Yu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:107 http://www.jeccr.com/content/29/1/107 Page 4 of 7 Table 2 The expression of BCL-2, BAD in youth and menopause human breast carcinoma Total BCL-2 Youth group menopause group 40 40 + 19 30 - 21 10 +(%) 47.5%a 75% BAD + 12 26 - 28 14 +(%) 30%b 65% The two groups compare with each other: a P < 0.05 b P < 0.05 2.1.3 The relationship between the expression of BCL-2, BAD and the histologic grade, clinical stage and the lymph node metastasis in human breast carcinoma The positive rates of BCL-2 in breast carcinoma histolo- gic grade I, II, III respectively were 84.61%, 58.69%, 12.50%, the difference have stastistical significance(P < 0.01), The positive rates of BCL-2 in breast cancer histo- logic grades I, II, III to assume the declining trend, sta- tistical analysis showed no significant difference (P = NS). In youth breast cancer histologic grade I, II, III the positive rates of BCL-2 were 87.5%, 44.4%, 0.0%(P < 0.01), and the rates of BAD were 50.0%, 29.6%, 0.0% (P = NS). In menopause breast cancer tissues histologic grade I to III the positive rates of BCL-2 were 88.9%, 73.7%, 0.0%, and the rates of BAD were 61.1%, 68.4%, 33.3% statistical analysis both showed no significant dif- ference, (P = NS). The positive rates of BCL-2 and BAD were all showed declining trend in the clinical TNM stage from I to IV of youth and menopause breast cancer tissues, but, the difference has no significance (P = NS). The positive rates of BCL-2 were 15.8% in the youth breast cancer tissues had axillary lymph nodes metasta- sis, the rates were 76.2% which had no axillary lymph node metastasis(P < 0.01); But the positive rates of BAD showed no relationship with the axillary lymph nodes metastasis. In the menopause breast cancer tissues the positive rates were 20.0% in the axillary lymph nodes metastasis group and 93.3% in control group(P < 0.01); The positive rates of BAD also showed no relationship with the axillary lymph node metastasis in menopause breast cancer tissues(P = NS) (Table 3). 2.1.4 The relationship between the expression of BCL-2, BAD and the expression of ER, PR All the breast cancer tissues in this study, 9 tissues with the expression of BCL-2 and BAD were positive;In this 9 tissues ER(+)PR(+) of 6 cases(66.7%), ER(+)PR(-) of 2 cases(22.2%), ER(-)PR(+) of 1 case(11.0%), ER(-)PR(-) was 0, When ER(+)PR(+) the positive co-expression rates of BCL-2 and BAD were significantly higher than the other three groups, there were significant differences (P < 0.05). In the 40 cases tissues with BCL-2(+)BAD(-) 18 cases were ER(+)PR(+)(45.0%),10 case were ER(+)PR (-) (25.0%),7 cases were ER(-)PR(+),5 cases were ER(-) PR(-), the difference had no significant difference (P = NS). There were 22 cases with BCL-2(-)BAD(+), which including ER(+)PR(+) 6 cases(27.3%), ER(+)PR(-) 7 cases(31.8%), ER(-)PR(+) 8 cases(36.4%), ER(-)PR(+) 1 case(4.5%), the difference also had no significance (P = NS). There were 9 cases which the co-expression of BCL-2 and BAD were negative, ER(+)PR(-) was 1 case(11.1%), ER(-)PR(-) were 8 cases(88.9%), ER(+)PR(+) and ER(-) PR(+) were all 0;The negative co-expression rates of BCL-2 and BAD in the ER(-)PR(-) group were signifi- cantly higher than the other three groups (P < 0.05). (Table 4) 2.2.1 The Sensitivity Of Breast Cancer Cells To Anticancer Drugs In Vitro The mean relative inhibition rate of breast cancer cells are EADM(69.74 ± 7.67)%, 5-Fu(61.81 ± 9.94)%, NVB (69.10 ± 8.27)%, DDP(63.27 ± 6.79)% in 10 × PPC. The numerus are EADM(45.39 ± 11.74)%, 5-Fu(44.56 ± 12.28)%, NVB(48.50 ± 9.96)%, DDP(41.42 ± 4.81)% in 1 × PPC and EADM(27.57 ± 8.94)%, 5-Fu(25.48 ± 8.62)%, NVB(30.35 ± 9.02)%, DDP(25.33 ± 5.65)% in 0.1 × PPC. Along with drug concentrating reduction, breast cancer cancer cell’s inhibition rate relatively reduces gra- dually. The sensitivity of breast cancer cells to the 4 kinds of drugs in 0.1 × PPC are as follow EADM 30%, 5-Fu 20%, NVB 45%, DDP 25%(Table. 5). 2.2.2 The Relationship Between The Expression Of BCL-2, BAD And The Chemosensitivity Of The Breast Cancer Cells In 0.1 × PPC In Vitro In the drug sensitivity test in vitro of breast cancer cells of 4 kinds of chemotherapeutic agents in 0.1 × PPC, the chemosensitivity and the expression level of BCL-2 are related, the chemosensitivity of the BCL-2(-) tumor cells was higher than the BCL-2(+) tumor cells(Table. 6), and there was a negative correlation between the the expres- sion of BCL-2 and the chemosensitivity of the 4 drugs (P < 0.05). In the test the sensitivity to EADM and NVB were associated with the expression of BAD, The BAD (+)tumour cells were more sensitivity to EADM and NVB than the BAD(-)ones(P < 0.05)(Table. 7). and there was a positive correlation between the the expression of BAD and the chemosensitivity to EADM and NVB. In the tumour cells which were BCL-2(-)BAD(+) the che- mosensitivity to the 4 drugs were higher than the BCL-2 (+)BAD(+)and BCL-2(+)BAD(-)ones. The breast cancer cells in which BCL-2 and BAD were all positive were more chemosensitive to NVB than the BCL-2(+)BAD(-) ones(P < 0.05); In the tumour cells which were BCL-2(-) BAD(+), BCL-2(+)BAD(-)the chemosensitivity to NVB was higher than to the other 3 drugs, but there were no significant differences(P = NS)(Table. 8).